Alzheimer's disease

After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug
NPR
Sat, 05/4/19 - 02:35 pm
Alzheimer's disease
R&D
drug development
beta amyloid
Biogen
Eisai
aducanumab
Biogen says it will not give up on Alzheimer’s after failed trials
Marketwatch
Sun, 04/28/19 - 12:18 pm
Biogen
drug development
Alzheimer's disease
Biogen cans plan to test aducanumab in Alzheimer's prevention
Fierce Biotech
Wed, 04/24/19 - 12:00 pm
Biogen
Alzheimer's disease
aducanumab
cilnical trials
What does the past generation of failure in Alzheimer’s R&D look like in one slide?
Endpoints
Wed, 04/24/19 - 11:45 am
R&D
Alzheimer's disease
amyloid beta
Eli Lilly
Pfizer
JNJ
EIP bags cash to trial ex-Vertex drug in dementia, Huntington's
Fierce Biotech
Mon, 04/15/19 - 10:00 am
EIP Pharma
Alzheimer's disease
dementia
Huntington's disease
Clinical-Stage Neurodegenerative Disease Company Files for $86 Million IPO
CP Wire
Mon, 04/15/19 - 09:58 am
Cortexyme
IPOs
COR388
Alzheimer's disease
Clinical-Stage Neurodegenerative Disease Company Files for $86 Million IPO
Mon, 04/15/19 - 09:56 am
Cortexyme
IPOs
COR388
Alzheimer's disease
Alzheimer's-focused M3 Biotechnology rebrands as Athira Pharma
Fierce Biotech
Fri, 04/12/19 - 12:04 am
M3 Biotechnology
rebranding
Athira Pharma
Alzheimer's disease
Should Biogen Investors Be Extra Nervous Right Now?
Motley Fool
Sun, 04/7/19 - 05:08 pm
Biogen
Alzheimer's disease
ICER
investors
Spinraza
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Motley Fool
Sat, 03/30/19 - 12:44 pm
Alzheimer's disease
Biogen
aducanumab
Otsuka
Axsome Therapeutics
Amgen
Novartis
Avanir
AVP-786
AXS-05
AMG520
What Are Biopharma Leaders Focused on?
BioSpace
Wed, 03/27/19 - 10:32 am
drug pricing
regulatory
innovation
value-based drug pricing
government
Alzheimer's disease
drug manufacturing
Avanir's AVP-786 meets in Phase III for Alzheimer's agitation
BioCentury
Mon, 03/25/19 - 10:28 pm
Avanir Pharmaceuticals
AVP-786
Alzheimer's disease
Alzheimer's agitation
1 Surprising Reason Alzheimer's Drugs Remain So Elusive
Motley Fool
Mon, 03/25/19 - 10:13 pm
R&D
Alzheimer's disease
drug development
sleep science
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
EP Vantage
Mon, 03/25/19 - 11:57 am
Biogen
Alzheimer's disease
Tecfidera
generics
Mylan
Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge
Marketwatch
Mon, 03/25/19 - 10:08 am
Biogen
Alzheimer's disease
stock buyback
Is a severely damaged Biogen looking to shed its ties to a controversial development partner?
Endpoints
Sat, 03/23/19 - 12:07 pm
Biogen
Eisai
Alzheimer's disease
BAN2401
FDA panel: Neuronix Alzheimer’s therapy fails to prove efficacy
Medical Design and Outsourcing
Fri, 03/22/19 - 10:03 pm
Neuronix
Alzheimer's disease
devices
NeuroAD
transcranial magnetic stimulation
RIP amyloid beta theory? Nope. Biogen partner launches a new PhIII before aducanumab's corpse turned cold
Endpoints
Fri, 03/22/19 - 11:58 am
Biogen
Eisai
BAN2401
Alzheimer's disease
clinical trials
How Will The Failure Of Biogen's Alzheimer's Drug, Aducanumab, Impact R&D?
Forbes
Fri, 03/22/19 - 10:22 am
Biogen
R&D
Alzheimer's disease
Where can Biogen turn after mammoth Alzheimer's blow? The M&A table, analysts say
Fierce Pharma
Thu, 03/21/19 - 12:28 pm
Biogen
Alzheimer's disease
aducanumab
M&A

Pages